Avid Bioservices Inc (CDMO)

[md1225]

ex Bavi will be used in combo to make the PD-1 more efficacious in my opinion we are NOT competing but if we were the data we need to best is the intent-to-treat (ITT) population, Opdivo significantly improved OS compared to docetaxel. Treatment with Opdivo resulted in a 27 per cent reduction in the risk of death, amounting to a 2.8-month difference at the median (12.2 months vs. 9.4 months).